800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

view all Clinical Trials

Overview

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).

Clinical Trial Information

Protocol

TIRB#: 32116

Phase

2

Condition(s)

Bronchiectasis

Investigator

Daniel Salerno, MD

Coordinator

Kim Selwood

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis